The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease
Microbiology & Infectious Diseases · 2017
DOI: 10.33425/2639-9458.1009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology & Infectious Diseases, 2017. Verfasst von Martins IJ.
Abstract (Originalsprache)
Editorial Interests in global organ diseases have accelerated with links between nonalcoholic fatty liver disease (NAFLD) and various chronic diseases with relevance to the metabolic syndrome and neurodegenerative diseases. Early diagnosis of global organ disease involve genomic, lipidomic and proteomic biomarker tests that may diagnose early neuron dysfunction with the prevention of various organ diseases [1]. Diet and nutrition are closely linked to accelerated aging and may allow biomarker tests to provide adequate information with relevance to the immune system dysfunction and the severity of chronic diseases. In spite of various biomarker tests and analyte measurements for chronic diseases such as obesity and diabetes abnormal nuclear-mitochondria interactions [2] persist with inflammation involved in the induction of programmed cell death.
Zitieren
APA
IJ, M. (2017). The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease. Microbiology & Infectious Diseases. https://doi.org/10.33425/2639-9458.1009
Vancouver
IJ M. The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease. Microbiology & Infectious Diseases. 2017. doi:10.33425/2639-9458.1009
BibTeX
@article{IJ2017,
author = {IJ, Martins},
title = {The Future of Biomarkers Tests and Genomic Medicine in Global Organ Disease},
journal = {Microbiology & Infectious Diseases},
year = {2017},
doi = {10.33425/2639-9458.1009}
}
EUVIMED